| Gene symbol | CCNG1 | Synonyms | CCNG | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q34 | dbXrefs | |
| Description | cyclin G1 | ||||
| GTO ID | GTC2351 |
| Trial ID | NCT04378244 |
| Disease | COVID-19 |
| Altered gene | CCNG1 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | DeltaRex-G |
| Phase | Phase1|Phase2 |
| Recruitment status | Withdrawn |
| Title | CORONA: A Phase 1/2 Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 |
| Year | 2020 |
| Country | United States |
| Company sponsor | Aveni Foundation |
| Other ID(s) | AF20-203 |
| Vector information | |||||
|
|||||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||
| Cohort3: dose level 3 | |||||||
|
|||||||